Literature DB >> 11389482

Single-amino-acid deletion in the RYR1 gene, associated with malignant hyperthermia susceptibility and unusual contraction phenotype.

N Sambuughin1, S McWilliams, A de Bantel, K Sivakumar, T E Nelson.   

Abstract

Malignant hyperthermia (MH) is an anesthetic-drug-induced, life-threatening hypermetabolic syndrome caused by abnormal calcium regulation in skeletal muscle. Often inherited as an autosomal dominant trait, MH has linkage to 30 different mutations in the RYR1 gene, which encodes a calcium-release-channel protein found in the sarcoplasmic reticulum membrane in skeletal muscle. All published RYR1 mutations exclusively represent single-nucleotide changes. The present report documents, in exon 44 of RYR1 in two unrelated, MH-susceptible families, a 3-bp deletion that results in deletion of a conserved glutamic acid at position 2347. This is the first deletion, in RYR1, found to be associated with MH susceptibility. MH susceptibility was confirmed among some family members by in vitro diagnostic pharmacological contracture testing of biopsied skeletal muscle. Although a single-amino-acid deletion appears to be a subtle change in the protein, the deletion of Glu2347 from RYR1 produces an unusually large electrically evoked contraction tension in MH-positive individuals, suggesting that this deletion produces an alteration in skeletal-muscle calcium regulation, even in the absence of pharmacological agents.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11389482      PMCID: PMC1226035          DOI: 10.1086/321270

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  15 in total

Review 1.  Genetics and pathogenesis of malignant hyperthermia.

Authors:  K Jurkat-Rott; T McCarthy; F Lehmann-Horn
Journal:  Muscle Nerve       Date:  2000-01       Impact factor: 3.217

2.  Malignant hyperthermia in infancy and identification of novel RYR1 mutation.

Authors:  D Chamley; N A Pollock; K M Stowell; R L Brown
Journal:  Br J Anaesth       Date:  2000-04       Impact factor: 9.166

3.  Sarcoplasmic reticulum calcium uptake in cryostat sections of skeletal muscle from malignant hyperthermia patients and controls.

Authors:  P D Allen; J F Ryan; D E Jones; K Mabuchi; A Virga; J Roberts; F Sreter
Journal:  Muscle Nerve       Date:  1986-06       Impact factor: 3.217

Review 4.  Current concepts. The malignant hyperthermia syndrome.

Authors:  T E Nelson; E H Flewellen
Journal:  N Engl J Med       Date:  1983-08-18       Impact factor: 91.245

5.  Identification and functional characterization of a novel ryanodine receptor mutation causing malignant hyperthermia in North American and South American families.

Authors:  N Sambuughin; T E Nelson; J Jankovic; C Xin; G Meissner; M Mullakandov; J Ji; H Rosenberg; K Sivakumar; L G Goldfarb
Journal:  Neuromuscul Disord       Date:  2001-09       Impact factor: 4.296

6.  Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1).

Authors:  M C Roberts; J R Mickelson; E E Patterson; T E Nelson; P J Armstrong; D B Brunson; K Hogan
Journal:  Anesthesiology       Date:  2001-09       Impact factor: 7.892

7.  North American malignant hyperthermia population: screening of the ryanodine receptor gene and identification of novel mutations.

Authors:  N Sambuughin; Y Sei; K L Gallagher; H W Wyre; D Madsen; T E Nelson; J E Fletcher; H Rosenberg; S M Muldoon
Journal:  Anesthesiology       Date:  2001-09       Impact factor: 7.892

8.  A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.

Authors:  R L Brown; A N Pollock; K G Couchman; M Hodges; D O Hutchinson; R Waaka; P Lynch; T V McCarthy; K M Stowell
Journal:  Hum Mol Genet       Date:  2000-06-12       Impact factor: 6.150

9.  An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor.

Authors:  N Monnier; N B Romero; J Lerale; Y Nivoche; D Qi; D H MacLennan; M Fardeau; J Lunardi
Journal:  Hum Mol Genet       Date:  2000-11-01       Impact factor: 6.150

10.  Effects of halothane on mechanical response of skeletal muscle from malignant hyperthermia susceptible patients.

Authors:  T S Etchrivi; P J Adnet; B Tavernier; A Diallo; G Haudecoeur; R M Krivosic-Horber
Journal:  Arch Physiol Biochem       Date:  1998-10       Impact factor: 4.076

View more
  11 in total

1.  Basal bioenergetic abnormalities in skeletal muscle from ryanodine receptor malignant hyperthermia-susceptible R163C knock-in mice.

Authors:  Cecilia Giulivi; Catherine Ross-Inta; Alicja Omanska-Klusek; Eleonora Napoli; Danielle Sakaguchi; Genaro Barrientos; Paul D Allen; Isaac N Pessah
Journal:  J Biol Chem       Date:  2010-10-26       Impact factor: 5.157

2.  DICER1 mutations in embryonal rhabdomyosarcomas from children with and without familial PPB-tumor predisposition syndrome.

Authors:  Leslie Doros; Jiandong Yang; Louis Dehner; Christopher T Rossi; Kerry Skiver; Jason A Jarzembowski; Yoav Messinger; Kris Ann Schultz; Gretchen Williams; Nicolas André; D Ashley Hill
Journal:  Pediatr Blood Cancer       Date:  2011-12-16       Impact factor: 3.167

3.  Screening for mutations in the RYR1 gene in families with malignant hyperthermia.

Authors:  Viviane P Muniz; Helga C A Silva; Ana Maria C Tsanaclis; Mariz Vainzof
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

4.  Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States.

Authors:  Barbara W Brandom; Saiid Bina; Cynthia A Wong; Tarina Wallace; Mihaela Visoiu; Paul J Isackson; Georgirene D Vladutiu; Nyamkhishig Sambuughin; Sheila M Muldoon
Journal:  Anesth Analg       Date:  2013-04-04       Impact factor: 5.108

5.  Antibody probe study of Ca2+ channel regulation by interdomain interaction within the ryanodine receptor.

Authors:  Shigeki Kobayashi; Takeshi Yamamoto; Jerome Parness; Noriaki Ikemoto
Journal:  Biochem J       Date:  2004-06-01       Impact factor: 3.857

6.  Germline mutations in RYR1 are associated with foetal akinesia deformation sequence/lethal multiple pterygium syndrome.

Authors:  Arthur B McKie; Atif Alsaedi; Julie Vogt; Kyra E Stuurman; Marjan M Weiss; Hassan Shakeel; Louise Tee; Neil V Morgan; Peter G J Nikkels; Gijs van Haaften; Soo-Mi Park; Jasper J van der Smagt; Marianna Bugiani; Eamonn R Maher
Journal:  Acta Neuropathol Commun       Date:  2014-12-05       Impact factor: 7.801

7.  Functional analysis of RYR1 variants linked to malignant hyperthermia.

Authors:  Jeremy Stephens; Anja H Schiemann; Cornelia Roesl; Dorota Miller; Sean Massey; Neil Pollock; Terasa Bulger; Kathryn Stowell
Journal:  Temperature (Austin)       Date:  2016-02-26

8.  Whole exome sequencing of a patient with suspected mitochondrial myopathy reveals novel compound heterozygous variants in RYR1.

Authors:  Patrick R Blackburn; Duygu Selcen; Jennifer M Gass; Jessica L Jackson; Sarah Macklin; Margot A Cousin; Nicole J Boczek; Eric W Klee; Elliot L Dimberg; Kathleen D Kennelly; Paldeep S Atwal
Journal:  Mol Genet Genomic Med       Date:  2017-03-30       Impact factor: 2.183

Review 9.  Malignant hyperthermia.

Authors:  Henry Rosenberg; Mark Davis; Danielle James; Neil Pollock; Kathryn Stowell
Journal:  Orphanet J Rare Dis       Date:  2007-04-24       Impact factor: 4.123

Review 10.  Central core disease.

Authors:  Heinz Jungbluth
Journal:  Orphanet J Rare Dis       Date:  2007-05-15       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.